Abstract
The HeartMate 3 Left Ventricular Assist system (LVAS) has demonstrated enhanced hemocompatibility, with absence of de-novo pump thrombosis. However, clinically observed bleeding-related adverse events continue to remain significantly burdensome. We hypothesized that the enhanced hemocompatibility of the HeartMate 3 LVAS allows the safe use of decreased anticoagulation intensity, potentially decreasing bleeding-related adverse events.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
